{"prompt": "['Infusion-Related Reactions', 'Severity Grade of the Event (NCI CTCAE', 'Dose Modifications', 'Toxicity Management', 'version 4.03)', 'Any Grade', 'General Guidance', 'For Any Grade:', '-', 'Manage per institutional standard at the discretion of investigator.', '-', 'Monitor patients for signs and symptoms of infusion-related reactions', '(e.g., fever and/or shaking chills, flushing and/or itching, alterations in', 'heart rate and blood pressure, dyspnea or chest discomfort, or skin rashes)', 'and anaphylaxis (e.g., generalized urticaria, angioedema, wheezing,', 'hypotension, or tachycardia).', 'Grade 1 or 2', 'For Grade 1:', 'For Grade 1 or 2:', '-', 'The infusion rate of study drug/study regimen may be decreased', 'Acetaminophen and/or antihistamines may be administered per', 'institutional standard at the discretion of the investigator.', 'by 50% or temporarily interrupted until resolution of the event.', '-', 'Consider premedication per institutional standard prior to subsequent', 'doses.', '-', 'For Grade 2:', 'Steroids should not be used for routine premedication of Grade 2 infusion', 'reactions.', 'The infusion rate of study drug/study regimen may be decreased', '50% or temporarily interrupted until resolution of the event.', 'Subsequent infusions may be given at 50% of the initial', 'infusion rate.', 'Grade 3 or 4', 'For Grade 3 or 4:', 'For Grade 3 or 4:', '-', 'Permanently discontinue study drug/study regimen.', 'Manage severe infusion-related reactions per institutional standards (e.g.,', 'IM epinephrine, followed by IV diphenhydramine and ranitidine, and IV', 'glucocorticoid).', 'CTCAE Common Terminology Criteria for Adverse Events; IM intramuscular; IV intravenous; NCI National Cancer Institute.', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 109 de 123']['Non-Immune-Mediated Reactions', 'Severity Grade of the Event (NCI CTCAE', 'Dose Modifications', 'Toxicity Management', 'version 4.03)', 'Any Grade', 'Note: Dose modifications are not required for AEs not deemed to', 'Treat accordingly, as per institutional standard.', 'be related to study treatment (i.e., events due to underlying', 'disease) or for laboratory abnormalities not deemed to be', 'clinically significant.', 'Grade 1', 'No dose modifications.', 'Treat accordingly, as per institutional standard.', 'Grade 2', 'Hold study drug/study regimen until resolution to Grade 1 or', 'Treat accordingly, as per institutional standard.', 'baseline.', 'Grade 3', 'Hold study drug/study regimen until resolution to <Grade 1 or', 'Treat accordingly, as per institutional standard.', 'baseline.', 'For AEs that downgrade to Grade 2 within 7 days or resolve to', '<Grade 1 or baseline within 14 days, resume study drug/study', 'regimen administration. Otherwise, discontinue study drug/study', 'regimen.', 'Grade 4', 'Discontinue study drug/study regimen (Note: For Grade 4 labs,', 'Treat accordingly, as per institutional standard.', 'decision to discontinue should be based on accompanying', \"clinical signs/symptoms, the Investigator's clinical judgment, and\", 'consultation with the Sponsor.).', 'Note: As applicable, for early phase studies, the following sentence may be added: \"Any event greater than or equal to Grade 2, please discuss with Study Physician.\"', 'AE Adverse event; CTCAE Common Terminology Criteria for Adverse Events; NCI National Cancer Institute.', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 110 de 123'][\"APPENDIX 9: SUMMARY OF CHARACTERISTICS PRODUCT AND INVESTIVATOR'S\", 'BROCHURE', 'R', 'SmPC - FLUOROURACILE TEVA', 'http://base-donnees-publique.medicaments.gouv.fr/', 'SmPC-ELVORINE', 'http://base-donnees-publique.medicaments.gouv.fi', 'SmPC-IRINOTECAN', 'http://base-donnees-publique.medicaments.gouv.fr/', 'INFORMATIONS ON DURVALUMAB AND TREMILIMUMAB WILL BE', \"PROVIDED IN THE INVESTIGATOR'S BROCHURE\", 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 111 de 123']\n\n###\n\n", "completion": "END"}